• Special Issue Topic

    Exploring NAFLD/NASH

    Submission Deadline: June 01, 2020

    Guest Editors

    Dr. Amedeo Lonardo E-Mail

    Director of Simple Operating Unit, Ospedale Civile di Baggiovara, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy

    Research Keywords: NAFLD; NASH; cirrhosis; HCC


    Dr. Giovanni Targher E-Mail

    Section of Endocrinology and Metabolism, Department of Medicine, University of Verona, Verona, Italy

    Research Keywords: role of NAFLD in cardiovascular morbidity/mortality; role of NAFLD in microvascular complications of diabetes


    About the Special Issue

    Exploration of Medicine (EM) is a novel peer-reviewed, open access, online journal. It publishes articles that provide substantial and novel insights into medicine spanning molecular and cell biology through research of all human diseases. The journal adopts a single-blind peer review. Those authors who publish for EM hold the copyright of their works, make their original works completely available and free to use as long as the authors and the original source are properly cited.

    EM has charged two Associate Editors, Dr. Lonardo (Gastroenterology & Hepatology) and Professor Targher (Endocrinology & Metabolism) to edit a special issue dedicated to nonalcoholic fatty liver disease (NAFLD). Why has this topic been chosen? NAFLD defines a spectrum of hepatic (steatosis, nonalcoholic steatohepatitis [NASH], cirrhosis and hepatocellular carcinoma) and extra-hepatic manifestations (nephro-cardio-metabolic diseases and extra-hepatic cancers) that occur in individuals free of any competing causes of hepatic steatosis (e.g., alcohol, virus, drugs and others) but who often have concurrent dysmetabolic features. NAFLD is the most common chronic liver disease worldwide, causes considerable health care expenses, requests a heavy toll in terms of morbidity and premature mortality and has, therefore, gained considerable scientific interest. Areas of ongoing research include epidemiological features and risk factors, (molecular) pathogenesis, (non-invasive) diagnosis, government of the patients fluxes from primary to specialist care as well as management of this burdensome liver disease with lifestyle modifications and innovative drugs that are being evaluated.

    In order to provide a virtual forum for exchange of ideas and data in Academic as well as in Translational and Clinical research, Dr. Lindsay Farrer, the Editor-in-Chief of EM, has invited Doctors Lonardo and Targher to edit this single-topic issue.

    Keywords: NAFLD; NASH; HCC; cirrhosis

    Published Articles

    Open Access
    Review
    Pediatric vs. adult NAFLD to MAFLD transition: a welcome but tangled path
    The term non-alcoholic fatty liver disease (NAFLD) appears unfitting both in adults and in children. As obesity and metabolic syndrome play a relevant pathogenic role, an international group of adults’ liver disease experts has  [...] Read more.
    Angelo Colucci ... Claudia Mandato
    Published: August 31, 2021 Explor Med. 2021;2:333–342
    DOI: https://doi.org/10.37349/emed.2021.00051
    Open Access
    Review
    Sex hormones abnormalities in non-alcoholic fatty liver disease: pathophysiological and clinical implications
    Obesity and metabolic syndrome are conditions at high risk for the development of complications such as type 2 diabetes mellitus, atherosclerotic cardiovascular disease, and non-alcoholic fatty liver disease (NAFLD). The growing p [...] Read more.
    Angelo Di Vincenzo ... Marco Rossato
    Published: August 31, 2021 Explor Med. 2021;2:311–323
    DOI: https://doi.org/10.37349/emed.2021.00049
    View:712
    Download:49
    Times Cited: 0
    Open Access
    Review
    Cardiovascular involvement after liver transplantation: role of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
    Patients submitted to liver transplantation (LT) are exposed to high risk of cardiovascular (CV) complications which are the main determinants of both short-term and long-term morbidity and mortality in LT. Non-alcoholic fatty liv [...] Read more.
    Rosa Lombardi ... Anna Ludovica Fracanzani
    Published: February 28, 2021 Explor Med 2021;2:20–38
    DOI: https://doi.org/10.37349/emed.2021.00030
    View:1019
    Download:24
    Times Cited: 0
    Open Access
    Review
    The diagnostic conundrum in non-alcoholic fatty liver disease
    Non-alcoholic fatty liver disease (NAFLD) has become the most common liver alteration worldwide. It encompasses a spectrum of disorders that range from simple steatosis to a progressive form, defined non-alcoholic steatohepatitis  [...] Read more.
    Valerio Rosato ... Marcello Persico
    Published: October 30, 2020 Explor Med. 2020;1:259–286
    DOI: https://doi.org/10.37349/emed.2020.00018
    View:2873
    Download:101
    Open Access
    Review
    Nonalcoholic fatty liver disease and type 2 diabetes: pathophysiological mechanisms shared between the two faces of the same coin
    The pathophysiological mechanisms underlying the close relationship between nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) are multiple, complex and only partially known. The purpose of this paper was [...] Read more.
    Carlo Acierno ... Ferdinando Carlo Sasso
    Published: October 30, 2020 Explor Med. 2020;1:287–306
    DOI: https://doi.org/10.37349/emed.2020.00019
    View:2949
    Download:105
    Open Access
    Review
    Non-alcoholic fatty liver disease and transient elastography
    Nonalcoholic fatty liver disease (NAFLD) is a serious condition that can lead to fibrosis, cirrhosis, and hepatocellular carcinoma. NAFLD is associated with metabolic syndrome (MetS) and all of its components. According to data, a [...] Read more.
    Ivana Mikolasevic ... Sandra Milic
    Published: August 31, 2020 Explor Med. 2020;1:205–217
    DOI: https://doi.org/10.37349/emed.2020.00014
    View:3452
    Download:48
    Open Access
    Review
    Role of acetylation in nonalcoholic fatty liver disease: a focus on SIRT1 and SIRT3
    Nonalcoholic fatty liver disease (NAFLD) has become the most prevalent liver chronic disease worldwide. The pathogenesis of NAFLD is complex and involves many metabolic enzymes and multiple pathways. Posttranslational modification [...] Read more.
    Fatiha Nassir
    Published: August 31, 2020 Explor Med. 2020;1:248–258
    DOI: https://doi.org/10.37349/emed.2020.00017
    View:2613
    Download:66
    Open Access
    Review
    Genetic and metabolic factors: the perfect combination to treat metabolic associated fatty liver disease
    The prevalence of nonalcoholic or more recently re-defined metabolic associated fatty liver disease (MAFLD) is rapidly growing worldwide. It is characterized by hepatic fat accumulation exceeding 5% of liver weight not attributabl [...] Read more.
    Marica Meroni ... Paola Dongiovanni
    Published: August 31, 2020 Explor Med. 2020;1:218–243
    DOI: https://doi.org/10.37349/emed.2020.00015
    View:2856
    Download:75
    Open Access
    Review
    The therapeutic potential of C-C chemokine receptor antagonists in nonalcoholic steatohepatitis
    Pooled prevalence of nonalcoholic fatty liver disease (NAFLD) globally is about 25%. Nonalcoholic steatohepatitis (NASH) with advanced fibrosis has been linked with substantial morbidity and mortality, without having to-date any l [...] Read more.
    Michael Doulberis ... Stergios A. Polyzos
    Published: August 31, 2020 Explor Med. 2020;1:170–183
    DOI: https://doi.org/10.37349/emed.2020.00012
    View:2616
    Download:40
    Open Access
    Review
    Perspectives of nonalcoholic fatty liver disease research: a personal point of view
    Rational government of patient fluxes from primary care to hepatology clinic is a priority of nonalcoholic fatty liver disease (NAFLD) research. Estimating pre-test probability of disease, risk of fibrosis progression, and exclusi [...] Read more.
    Amedeo Lonardo, Stefano Ballestri
    Published: June 29, 2020 Explor Med. 2020;1:85–107
    DOI: https://doi.org/10.37349/emed.2020.00007
    Open Access
    Review
    Nonalcoholic fatty liver disease and portal hypertension
    Nonalcoholic fatty liver disease (NAFLD) is a substantial and growing problem worldwide and has become the second most common indication for liver transplantation as it may progress to cirrhosis and develop complications from port [...] Read more.
    Marvin Ryou ... Gyorgy Baffy
    Published: June 29, 2020 Explor Med. 2020;1:149–169
    DOI: https://doi.org/10.37349/emed.2020.00011
    Open Access
    Review
    Sex differences in non-alcoholic fatty liver disease: hints for future management of the disease
    Non-alcoholic fatty liver disease (NAFLD) remains a major cause of chronic liver disease worldwide. Despite extensive studies, the heterogeneity of the risk factors as well as different disease mechanisms complicate the goals towa [...] Read more.
    Noel C. Salvoza ... Natalia Rosso
    Published: April 30, 2020 Explor Med. 2020;1:51–74
    DOI: https://doi.org/10.37349/emed.2020.00005
    View:6534
    Download:151